# Ustar Biotechnologies (Hangzhou)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ustar-biotechnologies-hangzhou

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.bioustar.com
- Total disclosed funding: $47M
- Latest round: Series E (Nov 30, 2021)
- Investors on record: 4

## About

Based in Hangzhou, China and established in 2005, Ustar Biotechnologies (Hangzhou) Ltd is a biotechnology company that engaged in research and development of point of caretesting(POCT) technology and products. The company's technology has received support from the Bill & Melinda Gates Foundation, the World Health Organization (WHO) and other organizations.

The company focuses on POCT molecular diagnostic products and related technology such as constant temperature amplification technology and reagent vitrification technology. The company's products have covered more than 2,000 medical and health institutions in China and sold to about 60 countries.

Following the funding in 2021, the company plans to use the investment to increase the capacity of EasyNat's high-throughput nucleic acid amplification platform and test menu expansion, as well as the mass production of nucleic acid-based home self-testing platform and the development of next-generation testing platform.

## Funding rounds

- Series E, Nov 30, 2021, $47M — CPE Funds Management, Oriental Fortune Capital
- Series A, Jun 1, 2010 — Legend Capital, Huaou Equity Investment
- Angel, Mar 3, 2010 — Legend Capital

## Investors

- Legend Capital — Angel, Series A
- Huaou Equity Investment — Series A
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series E
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series E